Kirkland and Wachtell steer GSK/Pfizer joint venture

Pharmaceutical giants GlaxoSmithKline and Pfizer announced their plans to combine the companies’ consumer health businesses in a deal valued at approximately £9.8 billion (€10.8 billion).

Get unlimited access to all Global Competition Review content